Literature DB >> 17885356

FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment.

Masatoyo Nakajo1, Seishi Jinnouchi, Hirosaka Inoue, Maki Otsuka, Tadashi Matsumoto, Toshimasa Kukita, Hiroaki Tanabe, Rie Tateno, Masayuki Nakajo.   

Abstract

We report 2 patients with chronic myeloid leukemia in the chronic phase showing diffusely increased F-18 fluorodeoxyglucose (FDG) uptake in the bone marrow before treatment. Follow-up FDG positron emission tomography (PET) scans were performed in a patient after cessation of treatment and in the other under treatment. Both FDG PET findings showed reduced FDG uptake in the bone marrow. A series of these FDG PET findings suggest the usefulness of FDG PET for the diagnosis and monitoring of chronic myeloid leukemia after treatment.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17885356     DOI： 10.1097/RLU.0b013e318148b467

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  9 in total

1.  Unraveling the complex regulatory relationships between metabolism and signal transduction in cancer.

Authors:  Michelle L Wynn; Sofia D Merajver; Santiago Schnell
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

2.  Hyperostosis - an unusual radiographic presentation of Myelodysplastic Syndrome transformed to Acute Myeloid Leukemia.

Authors:  Arie Franco; Kristopher N Lewis; Joshua M Blackmon; Elizabeth J Manaloor
Journal:  J Radiol Case Rep       Date:  2010-11-01

3.  FDG-PET/CT findings in systemic mastocytosis: a French multicentre study.

Authors:  S Djelbani-Ahmed; M O Chandesris; A Mekinian; D Canioni; C Brouzes; K Hanssens; G Pop; I Durieu; S Durupt; B Grosbois; S Besnard; O Tournilhac; O Beyne-Rauzy; P Agapé; A Delmer; D Ranta; P Y Jeandel; S Georgin-Lavialle; L Frenzel; G Damaj; V Eder; O Lortholary; O Hermine; O Fain; M Soussan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-05       Impact factor: 9.236

4.  Myeloid Sarcoma and Acute Myelomonocytic Leukemia in an Adolescent with Tetrasomy 8: Staging with (18)F-FDG PET/CT.

Authors:  William Makis; Rajan Rakheja; Josee Lavoie; Marc Hickeson
Journal:  Nucl Med Mol Imaging       Date:  2012-02-14

5.  (124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.

Authors:  Mikhail Doubrovin; Tatiana Kochetkova; Elmer Santos; Darren R Veach; Peter Smith-Jones; Nagavarakishore Pillarsetty; Julius Balatoni; William Bornmann; Juri Gelovani; Steven M Larson
Journal:  J Nucl Med       Date:  2010-01       Impact factor: 10.057

Review 6.  Radionuclide imaging of bone marrow disorders.

Authors:  Ali Agool; Andor W J M Glaudemans; Hendrikus H Boersma; Rudi A J O Dierckx; Edo Vellenga; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

7.  Role of FDG PET/CT in Diagnostic Evaluation of Granulocytic Sarcomas: A Series of 12 Patients.

Authors:  Piyush Chandra; Sanket Dhake; Nilendu Purandare; Archi Agrawal; Sneha Shah; Venkatesh Rangarajan
Journal:  Indian J Nucl Med       Date:  2017 Jul-Sep

8.  A predicting model of bone marrow malignant infiltration in 18F-FDG PET/CT images with increased diffuse bone marrow FDG uptake.

Authors:  Mingge Zhou; Yumei Chen; Jianjun Liu; Gang Huang
Journal:  J Cancer       Date:  2018-04-19       Impact factor: 4.207

9.  Increased bone marrow uptake of 18F-FDG in leukemia patients: preliminary findings.

Authors:  Maya Kato Arimoto; Yuji Nakamoto; Koya Nakatani; Takayoshi Ishimori; Kouhei Yamashita; Akifumi Takaori-Kondo; Kaori Togashi
Journal:  Springerplus       Date:  2015-09-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.